Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
ACS Appl Mater Interfaces ; 16(19): 24248-24260, 2024 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-38693878

RESUMO

Biomedical devices are vulnerable to infections and biofilm formation, leading to extended hospital stays, high expenditure, and increased mortality. Infections are clinically treated via the administration of systemic antibiotics, leading to the development of antibiotic resistance. A multimechanistic strategy is needed to design an effective biomaterial with broad-spectrum antibacterial potential. Recent approaches have investigated the fabrication of innately antimicrobial biomedical device surfaces in the hope of making the antibiotic treatment obsolete. Herein, we report a novel fabrication strategy combining antibacterial nitric oxide (NO) with an antibiofilm agent N-acetyl cysteine (NAC) on a polyvinyl chloride surface using polycationic polyethylenimine (PEI) as a linker. The designed biomaterial could release NO for at least 7 days with minimal NO donor leaching under physiological conditions. The proposed surface technology significantly reduced the viability of Gram-negative Escherichia coli (>97%) and Gram-positive Staphylococcus aureus (>99%) bacteria in both adhered and planktonic forms in a 24 h antibacterial assay. The composites also exhibited a significant reduction in biomass and extra polymeric substance accumulation in a dynamic environment over 72 h. Overall, these results indicate that the proposed combination of the NO donor with mucolytic NAC on a polymer surface efficiently resists microbial adhesion and can be used to prevent device-associated biofilm formation.


Assuntos
Acetilcisteína , Antibacterianos , Biofilmes , Escherichia coli , Óxido Nítrico , Staphylococcus aureus , Acetilcisteína/química , Acetilcisteína/farmacologia , Óxido Nítrico/química , Óxido Nítrico/metabolismo , Óxido Nítrico/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Antibacterianos/farmacologia , Antibacterianos/química , Biofilmes/efeitos dos fármacos , Polietilenoimina/química , Polietilenoimina/farmacologia , Materiais Biocompatíveis/química , Materiais Biocompatíveis/farmacologia , Testes de Sensibilidade Microbiana , Cloreto de Polivinila/química , Doadores de Óxido Nítrico/química , Doadores de Óxido Nítrico/farmacologia
2.
J Colloid Interface Sci ; 664: 928-937, 2024 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-38503078

RESUMO

Bacteria-associated infections and thrombus formation are the two major complications plaguing the application of blood-contacting medical devices. Therefore, functionalized surfaces and drug delivery for passive and active antifouling strategies have been employed. Herein, we report the novel integration of bio-inspired superhydrophobicity with nitric oxide release to obtain a functional polymeric material with anti-thrombogenic and antimicrobial characteristics. The nitric oxide release acts as an antimicrobial agent and platelet inhibitor, while the superhydrophobic components prevent non-specific biofouling. Widely used medical-grade silicone rubber (SR) substrates that are known to be susceptible to biofilm and thrombus formation were dip-coated with fluorinated silicon dioxide (SiO2) and silver (Ag) nanoparticles (NPs) using an adhesive polymer as a binder. Thereafter, the resulting superhydrophobic (SH) SR substrates were impregnated with S-nitroso-N-acetylpenicillamine (SNAP, an NO donor) to obtain a superhydrophobic, Ag-bound, NO-releasing (SH-SiAgNO) surface. The SH-SiAgNO surfaces had the lowest amount of viable adhered E. coli (> 99.9 % reduction), S. aureus (> 99.8 % reduction), and platelets (> 96.1 % reduction) as compared to controls while demonstrating no cytotoxic effects on fibroblast cells. Thus, this innovative approach is the first to combine SNAP with an antifouling SH polymer surface that possesses the immense potential to minimize medical device-associated complications without using conventional systemic anticoagulation and antibiotic treatments.


Assuntos
Anti-Infecciosos , Trombose , Humanos , Óxido Nítrico/química , Prata/farmacologia , S-Nitroso-N-Acetilpenicilamina/química , S-Nitroso-N-Acetilpenicilamina/farmacologia , Staphylococcus aureus , Escherichia coli , Dióxido de Silício/farmacologia , Antibacterianos/farmacologia , Antibacterianos/química , Anti-Infecciosos/farmacologia , Interações Hidrofóbicas e Hidrofílicas , Trombose/prevenção & controle , Polímeros/química
3.
Macromol Biosci ; 21(1): e2000248, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33021079

RESUMO

The novel use of nanofibers as a physical barrier between blood and medical devices has allowed for modifiable, innovative surface coatings on devices ordinarily plagued by thrombosis, delayed healing, and chronic infection. In this study, the nitric oxide (NO) donor S-nitrosoglutathione (GSNO) is blended with the biodegradable polymers polyhydroxybutyrate (PHB) and polylactic acid (PLA) for the fabrication of hemocompatible, antibacterial nanofibers tailored for blood-contacting applications. Stress/strain behavior of different concentrations of PHB and PLA is recorded to optimize the mechanical properties of the nanofibers. Nanofibers incorporated with different concentrations of GSNO (10, 15, 20 wt%) are evaluated based on their NO-releasing kinetics. PLA/PHB + 20 wt% GSNO nanofibers display the greatest NO release over 72 h (0.4-1.5 × 10-10  mol mg-1 min-1 ). NO-releasing fibers successfully reduce viable adhered bacterial counts by ≈80% after 24 h of exposure to Staphylococcus aureus. NO-releasing nanofibers exposed to porcine plasma reduce platelet adhesion by 64.6% compared to control nanofibers. The nanofibers are found noncytotoxic (>95% viability) toward NIH/3T3 mouse fibroblasts, and 4',6-diamidino-2-phenylindole and phalloidin staining shows that fibroblasts cultured on NO-releasing fibers have improved cellular adhesion and functionality. Therefore, these novel NO-releasing nanofibers provide a safe antimicrobial and hemocompatible coating for blood-contacting medical devices.


Assuntos
Liberação Controlada de Fármacos/efeitos dos fármacos , Óxido Nítrico/biossíntese , S-Nitrosoglutationa/farmacologia , Infecções Estafilocócicas/tratamento farmacológico , Trombose/tratamento farmacológico , Animais , Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Modelos Animais de Doenças , Fibrinolíticos/química , Fibrinolíticos/farmacologia , Humanos , Hidroxibutiratos/química , Hidroxibutiratos/farmacologia , Camundongos , Células NIH 3T3 , Nanofibras/química , Óxido Nítrico/química , Adesividade Plaquetária/efeitos dos fármacos , Poliésteres/química , Poliésteres/farmacologia , Proibitinas , S-Nitrosoglutationa/química , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/patogenicidade , Suínos , Trombose/microbiologia , Trombose/patologia , Cicatrização/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA